Matches in Wikidata for { <http://www.wikidata.org/entity/Q63595001> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- Q63595001 description "clinical trial" @default.
- Q63595001 description "ensayu clínicu" @default.
- Q63595001 description "klinisch onderzoek" @default.
- Q63595001 description "клінічне випробування" @default.
- Q63595001 name "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations" @default.
- Q63595001 type Item @default.
- Q63595001 label "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations" @default.
- Q63595001 prefLabel "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations" @default.
- Q63595001 P1050 Q63595001-71A5F2AF-A6D0-45C3-945A-F4982D86F479 @default.
- Q63595001 P1132 Q63595001-00552E05-DFE5-4925-9C6F-C38E49172345 @default.
- Q63595001 P1476 Q63595001-4E796A21-EEA4-43F2-8086-673F059596E6 @default.
- Q63595001 P17 Q63595001-D641A3FF-D57A-4098-A4B6-953EC514250A @default.
- Q63595001 P2899 Q63595001-89F387B5-4193-421A-BD00-1B5771326A99 @default.
- Q63595001 P3098 Q63595001-B00E9F79-4560-4677-A3E9-E2DE6EF82131 @default.
- Q63595001 P31 Q63595001-894FD502-AF50-45D9-917D-2EB0AB81F5FE @default.
- Q63595001 P4844 Q63595001-29A10932-EC66-4424-9A07-E16F0DA1A19E @default.
- Q63595001 P4844 Q63595001-CC29691C-68ED-4CD9-AABD-090BC8C9D67A @default.
- Q63595001 P580 Q63595001-DFCF9F94-B655-4EF1-A02A-B29CBA012F34 @default.
- Q63595001 P582 Q63595001-85EBE17A-A3E1-4B15-A247-8CC59E2EFBD2 @default.
- Q63595001 P6099 Q63595001-09A05746-6395-4F97-993C-215072A1559F @default.
- Q63595001 P6153 Q63595001-015CCD51-5FA0-48E6-89CD-C3AFE65725BF @default.
- Q63595001 P6153 Q63595001-114D091B-3F37-4C7C-AFA6-3DA3ED6A8D10 @default.
- Q63595001 P6153 Q63595001-1551BDAB-3501-435C-A01F-1A83B960BABD @default.
- Q63595001 P6153 Q63595001-1E65D799-70C7-4187-BA1E-9C2A0F2C2B73 @default.
- Q63595001 P6153 Q63595001-2CF9A526-D995-47BD-862E-F4EDD2FDCAC1 @default.
- Q63595001 P6153 Q63595001-59B7033C-F7F1-4A8A-91B2-F5D9D0FA1368 @default.
- Q63595001 P6153 Q63595001-6C854821-6D91-4FDE-97FD-8CBA8FB04887 @default.
- Q63595001 P6153 Q63595001-74655D72-85E7-4947-B0A1-15CA9F67B090 @default.
- Q63595001 P6153 Q63595001-8431E170-E4B1-4FA0-BDD4-5657AFFF9612 @default.
- Q63595001 P6153 Q63595001-891553D7-46CC-48D3-9295-EA4DA8B3FAF1 @default.
- Q63595001 P6153 Q63595001-92413D3B-834B-4737-B018-288DB19F7AD5 @default.
- Q63595001 P6153 Q63595001-92FB28B5-C550-454F-8E08-8DFA91349D70 @default.
- Q63595001 P6153 Q63595001-A310E48C-43E7-4782-BD4E-064C4F7F4D47 @default.
- Q63595001 P6153 Q63595001-A8F0AC6E-DFDD-4AD2-8BE5-5C9E4DF05CFF @default.
- Q63595001 P6153 Q63595001-B331219B-6881-4667-B915-F52F424050B1 @default.
- Q63595001 P6153 Q63595001-B35BA79B-BBE9-45BB-85B9-F748DDD7C20C @default.
- Q63595001 P6153 Q63595001-B689A3CA-F064-4968-A9BA-BECCDA9E0C7C @default.
- Q63595001 P6153 Q63595001-CB29E5CD-9C52-493A-82F2-8F48EA8AACDA @default.
- Q63595001 P6153 Q63595001-CC6A8CAC-5BF4-43CB-9E31-B7511CF06835 @default.
- Q63595001 P6153 Q63595001-CCB07E0D-34DC-48F5-878C-F255FE84B783 @default.
- Q63595001 P6153 Q63595001-D48E30ED-94D7-4257-AA97-B838E0F15459 @default.
- Q63595001 P6153 Q63595001-D9AE725A-720E-4A28-83D9-D241E9D9126B @default.
- Q63595001 P6153 Q63595001-DC94FBF1-EBFE-4AAE-B38E-5AC591FF77B1 @default.
- Q63595001 P6153 Q63595001-ED955F3E-421F-44B5-9122-CF80E4E041E2 @default.
- Q63595001 P6153 Q63595001-F4FCFA82-B391-43C4-A863-50EA228EF8A4 @default.
- Q63595001 P6153 Q63595001-F575FFBF-4E06-4DE1-808A-B85A50EC4FAE @default.
- Q63595001 P8363 Q63595001-2B2AC37B-2538-4694-BD95-84A908E946DB @default.
- Q63595001 P1050 Q124292 @default.
- Q63595001 P1132 "+350" @default.
- Q63595001 P1476 "A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial" @default.
- Q63595001 P17 Q30 @default.
- Q63595001 P2899 "+18" @default.
- Q63595001 P3098 "NCT03773302" @default.
- Q63595001 P31 Q30612 @default.
- Q63595001 P4844 Q412415 @default.
- Q63595001 P4844 Q414143 @default.
- Q63595001 P580 "2019-03-01T00:00:00Z" @default.
- Q63595001 P582 "2021-10-31T00:00:00Z" @default.
- Q63595001 P6099 Q42824827 @default.
- Q63595001 P6153 Q1057447 @default.
- Q63595001 P6153 Q1317143 @default.
- Q63595001 P6153 Q1418766 @default.
- Q63595001 P6153 Q1525831 @default.
- Q63595001 P6153 Q1808012 @default.
- Q63595001 P6153 Q2892284 @default.
- Q63595001 P6153 Q30253372 @default.
- Q63595001 P6153 Q30270311 @default.
- Q63595001 P6153 Q309331 @default.
- Q63595001 P6153 Q3145341 @default.
- Q63595001 P6153 Q43896488 @default.
- Q63595001 P6153 Q4403855 @default.
- Q63595001 P6153 Q49210 @default.
- Q63595001 P6153 Q501758 @default.
- Q63595001 P6153 Q503415 @default.
- Q63595001 P6153 Q503419 @default.
- Q63595001 P6153 Q5188247 @default.
- Q63595001 P6153 Q5902531 @default.
- Q63595001 P6153 Q624119 @default.
- Q63595001 P6153 Q626804 @default.
- Q63595001 P6153 Q706177 @default.
- Q63595001 P6153 Q7373582 @default.
- Q63595001 P6153 Q7451677 @default.
- Q63595001 P6153 Q7896459 @default.
- Q63595001 P6153 Q812573 @default.
- Q63595001 P6153 Q855730 @default.
- Q63595001 P8363 Q78089383 @default.